JP2016501845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501845A5 JP2016501845A5 JP2015540806A JP2015540806A JP2016501845A5 JP 2016501845 A5 JP2016501845 A5 JP 2016501845A5 JP 2015540806 A JP2015540806 A JP 2015540806A JP 2015540806 A JP2015540806 A JP 2015540806A JP 2016501845 A5 JP2016501845 A5 JP 2016501845A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- androgen
- cdk8
- inhibitor inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 4
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 102100032187 Androgen receptor Human genes 0.000 claims 3
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 claims 3
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 239000003098 androgen Substances 0.000 claims 3
- 108010080146 androgen receptors Proteins 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000004544 DNA amplification Effects 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721134P | 2012-11-01 | 2012-11-01 | |
| US61/721,134 | 2012-11-01 | ||
| PCT/US2013/067990 WO2014071143A1 (en) | 2012-11-01 | 2013-11-01 | Method for treating prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501845A JP2016501845A (ja) | 2016-01-21 |
| JP2016501845A5 true JP2016501845A5 (enExample) | 2016-12-22 |
| JP6310470B2 JP6310470B2 (ja) | 2018-04-11 |
Family
ID=49641849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540806A Expired - Fee Related JP6310470B2 (ja) | 2012-11-01 | 2013-11-01 | 前立腺がんを処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9636342B2 (enExample) |
| EP (1) | EP2914266B1 (enExample) |
| JP (1) | JP6310470B2 (enExample) |
| KR (1) | KR20160014568A (enExample) |
| CA (1) | CA2890108C (enExample) |
| WO (1) | WO2014071143A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106282378A (zh) * | 2016-09-28 | 2017-01-04 | 湖北工业大学 | 一种用于细胞周期依赖性蛋白激酶8基因突变检测的试剂及应用 |
| WO2019055977A1 (en) | 2017-09-18 | 2019-03-21 | Chan Zuckerberg Biohub, Inc. | METHODS OF TREATING NEGATIVE TRIPLE BREAST CANCER |
| US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| US12281080B2 (en) | 2018-08-21 | 2025-04-22 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| CA3128377A1 (en) * | 2019-02-01 | 2020-08-06 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005327921A1 (en) * | 2004-11-01 | 2006-08-31 | University Of Southern California | Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| EP2547661A2 (en) * | 2010-03-16 | 2013-01-23 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
| EA027531B1 (ru) | 2011-09-13 | 2017-08-31 | Игорь Ронинсон | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB |
| KR20150023223A (ko) | 2012-02-02 | 2015-03-05 | 세넥스 바이오테크놀러지 인코포레이티드 | Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도 |
-
2013
- 2013-11-01 JP JP2015540806A patent/JP6310470B2/ja not_active Expired - Fee Related
- 2013-11-01 WO PCT/US2013/067990 patent/WO2014071143A1/en not_active Ceased
- 2013-11-01 KR KR1020157014380A patent/KR20160014568A/ko not_active Ceased
- 2013-11-01 US US14/439,127 patent/US9636342B2/en active Active
- 2013-11-01 CA CA2890108A patent/CA2890108C/en active Active
- 2013-11-01 EP EP13795625.6A patent/EP2914266B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan et al. | RETRACTED: role of autophagy as a survival mechanism for hypoxic cells in tumors | |
| MX2020013649A (es) | Composiciones y metodos para inhibir la actividad de la arginasa. | |
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| JP2016514165A5 (enExample) | ||
| MX2022001757A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. | |
| MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
| JP2016501845A5 (enExample) | ||
| PH12018500899A1 (en) | Compositions and methods for inhibiting arginase activity | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| SA519410025B1 (ar) | مثبطات ديميثيلاز-1 نوعي لللايسين | |
| MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
| JO3419B1 (ar) | مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr | |
| WO2015009856A3 (en) | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors | |
| PH12015501464A1 (en) | Histone demethylase inhibitors | |
| MX381342B (es) | Compuestos terapeuticos inhibidores. | |
| MX2016002178A (es) | Composiciones y metodos terapeuticos para la regresion acelerada de placa. | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| CA2908957C (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| PE20200444A1 (es) | Terapia de combinacion para cancer de prostata | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
| WO2013019093A3 (en) | Novel aniline derivatives and use thereof | |
| MX2015017035A (es) | Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis. | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease |